Nothing Special   »   [go: up one dir, main page]

AR029613A1 - Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. . - Google Patents

Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. .

Info

Publication number
AR029613A1
AR029613A1 ARP000100524A ARP000100524A AR029613A1 AR 029613 A1 AR029613 A1 AR 029613A1 AR P000100524 A ARP000100524 A AR P000100524A AR P000100524 A ARP000100524 A AR P000100524A AR 029613 A1 AR029613 A1 AR 029613A1
Authority
AR
Argentina
Prior art keywords
vehicle
formulations
beneficial agent
methods
stable
Prior art date
Application number
ARP000100524A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR029613A1 publication Critical patent/AR029613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un vehículo viscoso biocompatible estable, no acuoso, de fase unica, apto para la suspension de agentes benéficos y para dispensar dicho agente benéfico de manera homogénea durante un período de tiempo prolongado a la temperatura corporal y con bajos índices de flujo. El vehículo viscoso comprende por lo menos dos componentes seleccionados del grupo que consiste en un solvente, un tensioactivo y un polímero. Formulaciones que comprenden por lo menos un agente benéfico, como por ejemplo, un péptido, una proteína, un nucleotido, una hormona, un virus o un anticuerpo, etc., uniformemente suspendido en el vehículo, y que son aptas para ser almacenadas a temperaturas que oscilan entre frío y temperatura corporal durante períodos de tiempo prolongados, y para ser administradas de manera uniforme desde disposiciones para la administracion de fármacos con una velocidad de esfuerzo de corte a la salida entre 1 y 1 x 10-7 s-1; y métodos para preparar el vehículo y las formulaciones.
ARP000100524A 1999-02-08 2000-02-07 Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. . AR029613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08

Publications (1)

Publication Number Publication Date
AR029613A1 true AR029613A1 (es) 2003-07-10

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100524A AR029613A1 (es) 1999-02-08 2000-02-07 Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. .

Country Status (22)

Country Link
EP (2) EP1666026B2 (es)
JP (1) JP4861551B2 (es)
KR (2) KR100858856B1 (es)
CN (1) CN1232244C (es)
AR (1) AR029613A1 (es)
AT (2) ATE537811T1 (es)
AU (1) AU775904B2 (es)
CA (1) CA2361424C (es)
CO (1) CO5140096A1 (es)
CY (1) CY1119950T1 (es)
DE (1) DE60027272T2 (es)
DK (1) DK1666026T4 (es)
ES (2) ES2261190T3 (es)
HK (2) HK1041451B (es)
HU (1) HUP0200202A3 (es)
IL (1) IL144755A0 (es)
NO (1) NO20013861L (es)
NZ (1) NZ513441A (es)
PT (2) PT1152749E (es)
TW (2) TWI292716B (es)
WO (1) WO2000045790A2 (es)
ZA (1) ZA200106443B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
KR20050088196A (ko) * 2002-12-19 2005-09-02 알자 코포레이션 안정한 비수성 단일 상 겔 및 이식가능한 장치로부터전달하기 위한 이의 제형
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050008661A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
KR20060017749A (ko) 2003-03-31 2006-02-27 알자 코포레이션 내압 소멸 수단을 갖는 삼투성 펌프
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2006084139A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc. An implantable interferon-containing device
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and their uses
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN109260193A (zh) 2011-05-25 2019-01-25 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
WO2013063284A1 (en) 2011-10-25 2013-05-02 Onclave Therapeutics Antibody formulations and methods
BR112014017719A8 (pt) 2012-01-23 2017-07-11 Novaliq Gmbh Composições de proteína estabilizada baseadas em alcanos semifluorados
US10449164B2 (en) 2012-09-12 2019-10-22 Novaliq Gmbh Methods of treating ocular disorders using semifluorinated alkanes
ES2621226T3 (es) 2012-09-12 2017-07-03 Novaliq Gmbh Composiciones de alcanos semifluorados
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
JP7012075B2 (ja) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー 眼瞼炎の治療に使用するための医薬組成物
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
WO2019063551A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING LATANOPROST FOR USE IN THE TREATMENT OF OCULAR DISEASES
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
JP7292567B2 (ja) 2018-09-27 2023-06-19 ダーマリック セラピューティクス， インコーポレーテッド 局所日焼け止め製剤
EP4406533A3 (en) 2018-10-12 2024-10-09 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1993009763A1 (en) † 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
WO1994021262A1 (en) † 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1995001167A2 (en) † 1993-06-25 1995-01-12 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
AU679793B2 (en) † 1993-09-29 1997-07-10 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5869088A (en) * 1994-10-24 1999-02-09 Nikken Chemicals Co., Ltd Transdermal administration preparation of a 9-aminocyclopenta (b) quinoline
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
SK282121B6 (sk) * 1995-06-06 2001-11-06 F. Hoffmann-La Roche Ag Farmaceutický prostriedok obsahujúci terapeuticky účinné množstvo inhibítora proteinázy
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
DK0836506T4 (da) † 1995-06-07 2012-01-30 Ortho Mcneil Pharm Inc Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ES2227707T3 (es) † 1996-07-15 2005-04-01 Alza Corporation Nuevas formulaciones para la administracion transdermica de acetato de fluoxetina y de maleato de fluoxetina.
ATE229817T1 (de) † 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CA2591581C (en) * 1996-12-20 2013-01-29 Alza Corporation Gel composition and methods
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
TW200730199A (en) 2007-08-16
ZA200106443B (en) 2002-08-06
ES2379471T3 (es) 2012-04-26
PT1152749E (pt) 2006-08-31
EP1152749B1 (en) 2006-04-12
ES2261190T3 (es) 2006-11-16
EP1666026A2 (en) 2006-06-07
HK1094528A1 (en) 2007-04-04
CN1232244C (zh) 2005-12-21
CO5140096A1 (es) 2002-03-22
DK1666026T4 (da) 2015-05-04
HUP0200202A3 (en) 2009-08-28
CA2361424C (en) 2009-04-28
EP1152749A2 (en) 2001-11-14
WO2000045790A3 (en) 2000-12-07
AU3481600A (en) 2000-08-25
CA2361424A1 (en) 2000-08-10
EP1666026B1 (en) 2011-12-21
KR20080045300A (ko) 2008-05-22
NO20013861D0 (no) 2001-08-08
DE60027272D1 (de) 2006-05-24
ATE537811T1 (de) 2012-01-15
KR100858856B1 (ko) 2008-09-17
NZ513441A (en) 2004-01-30
EP1666026A3 (en) 2007-08-08
PT1666026E (pt) 2012-03-15
IL144755A0 (en) 2002-06-30
JP2002536315A (ja) 2002-10-29
DE60027272T2 (de) 2007-01-25
ATE322889T1 (de) 2006-04-15
EP1666026B2 (en) 2015-02-25
HK1041451A1 (en) 2002-07-12
AU775904B2 (en) 2004-08-19
DK1666026T3 (da) 2012-04-10
WO2000045790A2 (en) 2000-08-10
NO20013861L (no) 2001-09-20
HK1041451B (zh) 2006-12-01
KR20010101842A (ko) 2001-11-14
JP4861551B2 (ja) 2012-01-25
ES2379471T5 (es) 2015-05-26
HUP0200202A2 (hu) 2002-05-29
CY1119950T1 (el) 2018-12-12
CN1339962A (zh) 2002-03-13
TWI292716B (en) 2008-01-21

Similar Documents

Publication Publication Date Title
AR029613A1 (es) Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. .
AR014940A1 (es) Un portador para la liberacion de un agente bioactivo, un polimero poliester biodegradable, copolimeros y composiciones farmaceuticas que loscontienen.
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
JP2002536315A5 (es)
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
ATE109000T1 (de) System zur freisetzung von medikamenten und dessen herstellungsmethode.
PE20040675A1 (es) Formulaciones de deposito de liberacion controlada
AR046485A1 (es) Sistema de administracion para drogas y terapia celular
MX9306051A (es) Composicion desodorante en forma de barra de gel estable.
TR200001545T2 (tr) Plazma proteini içeren farmasötik bileşimler.
DK0888110T3 (da) Mikropartikler af en kompositgel som bærere for aktive midler
NZ306156A (en) Stable protein-phospholipid composition and its use as a carrier
FI874706A (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
AR023044A1 (es) Composicion farmaceutica soluble en agua en un complejo no ionico y uso del mismo
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
EP2106787A3 (en) Biodegradable block copolymeric compositions for drug delivery
EP1025840A3 (en) Oral drug compositions and methods
AR021656A1 (es) Una composicion detergente liquida, transparente o translucida, altamente diluyente por cizallamiento, y un proceso para preparar una composiciondetergente liquida que comprende una goma gellan.
KR970014759A (ko) 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
ATE545652T1 (de) Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
UA83350C2 (ru) Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
DE69819145D1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
CN1989439A (zh) 治疗葡萄膜炎的方法以及组合物
BR9806303A (pt) Sistema de distrituição de droga termoformado, e, unidade de dosagem

Legal Events

Date Code Title Description
FC Refusal